Iowa Hematology Oncology Conference: Emphasis on Precision-Guided Management

Des Moines, IA US
March 23, 2024

The "Iowa Hematology Oncology Conference: Emphasis on Precision-Guided Management" is an accredited continuous education to improve the care of cancer patients by educating cancer care providers about precision-guided management in hematology and oncology. Regional and national experts in the field will share comprehensive insights into the actionable molecular variations seen in common cancers. The event's format is tailored to promote active learning, enhance knowledge retention, and encourage practitioners to apply fresh insights into their clinical routines. Through didactics, case-centric discussions, and lively Q&A sessions, attendees can gain clarity, address uncertainties, and interact with hematology and oncology experts. This conference aims to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in precision-guided management in hematology and oncology.  It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Hematologists/ Oncologists
  • Oncology Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses
  • Researchers and others

ORGANIZING COMMITTEE

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Vishal Vashistha, MD - US Department of Veterans Affairs

Organizing Committee

Kartik Anand, MD - Mission Cancer+Blood

Amy Raedeker DNP, ARNP, AGACNP-BC, AOCNP - Mission Cancer+Blood

Maddie Koppin, PharmD - Mission Cancer+Blood

VENUE INFORMATION

A limited number of rooms have been booked at the Embassy Suites by Hilton Des Moines Downtown at a discounted nightly rate of $169 per room for this conference's attendees and sponsors. Please book your room at the link here by February 20, 2024 to receive the discounted group rate. 

Learning Objectives

  1. Review common molecular abnormalities in various cancers and the optimal timing to test for these abnormalities.
  2. Interpret the findings from next-generation sequencing and other biomarkers that indicate the likelihood of response to specific therapies while also understanding the inherent challenges.
  3. Apply optimal strategies centered on molecular-targeted treatments in the management of patients with cancer.
  4. Summarize emerging research, the mechanism of action, and the significance of new molecular-targeted treatments in managing cancer patients.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.
Course opens: 
11/06/2023
Course expires: 
06/15/2024
Event starts: 
03/23/2024 - 8:00am PDT
Event ends: 
03/23/2024 - 4:00pm PDT
Cost:
$150.00

March 23rd, 2024

All times are listed in Central Time (CT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome 

08:05AM  – 08:25 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:25 AM – 09:10 AM  Session 1 - Precision Oncology - General Concepts

Moderator: Mark Klein, MD

08:25 AM – 08:40 AM  Solid Tumor Genomic Testing - Vishal Vashistha, MD

08:40 AM – 08:55 AM  MRD in Hematologic Malignancies - Tara Graff, DO, MS

08:55 AM – 09:10 AM  Q and A


09:10 AM – 09:40 AM  Session 2 - GI Oncology

Moderator: Chandrikha Chandrasekharan, MBBS

09:10 AM – 09:25 AM  Keynote Lecture: Precision Guided Management of GI Cancers - Mridula Krishnan, MBBS

09:25 AM – 09:40 AM  Q and A


09:40 AM – 10:25 AM  Break & Exhibits

Product Theater Sponsored by Servier Pharmaceuticals in Mississippi Room

Topic: IDHentifying Appropriate MDS or AML patients to Treat With TIBSOVO (Ivosidenib tablets)

Speaker: Harry Erba, MD, PhD - Director of Leukemia Program at Duke Blood Cancer Center

*Non CME Activity*


10:25 AM – 11:25 AM  Session 3 - Breast Cancer

Moderator: Seema Harichand, MD

10:25 AM – 10:40 AM  Genomics in Breast Cancer - Sneha Phadke, DO, MPH

10:40 AM – 11:25 AM  Panel Discussion - Amulya Yellala, MBBS, MD


11:25 AM – 12:25 PM  Lunch & Exhibits

11:40 AM to 12:45 PM: Product Theater Sponsored by AstraZeneca in Mississippi Room

Topic: Lunch & Learn TRUPAQ

Speaker: Amy Krie, MD Allina Health Cancer Institute, Piper Breast Center

*Non CME Activity*


12:25 – 01:25 PM  Session 4 - GU Oncology

Moderator: Kartik Anand, MD

12:25 PM – 12:40 PM  Keynote Speech: Recent Advances in Molecular Guided Treatment of GU Malignancies - Yousef Zakharia, MD

12:40 PM – 01:25 PM  Panel Discussion - Bilal Rahim, MD; Benjamin Teply, MD; Nicholas Zorko, MD


01:25 PM – 02:25 PM  Session 5 - Lung Oncology

Moderator: Apar Ganti, MD

01:25 PM – 01:40 PM  Keynote Speech: Advances in Precision-guided Management of Lung Cancers - Muhammad Furqan, MD

01:40 PM – 02:25 PM  Panel Discussion - William Zeitler, MD; Mark Klein, MD; Robert Kratzke, MD


02:25 PM – 02:55 PM  Break & Exhibits


02:55 PM – 04:15 PM  Session 6 - Hematology

Moderator: James Armitage, MD

02:55 PM – 03:10 PM  Multiple Myeloma - Christopher Strouse, MD

03:10 PM – 03:25 PM  Myeloid Disorders - Vijaya Raj Bhatt, MBBS, MS

03:25 PM - 03:40 PM  CLL - Eric Mou, MD

03:40 PM – 04:15 PM  Panel Discussion - Tara Graff, DO, MS


04:15 PM - 04:20 PM  Adjourn

Embassy Suites by Hilton Des Moines Downtown
101 E Locust St
Des Moines, IA 50309
United States

A limited number of rooms have been booked at the Embassy Suites by Hilton Des Moines Downtown at a discounted nightly rate of $169 per room for this conference's attendees and sponsors. Please book your room at the link here by February 20, 2024 to receive the discounted group rate. 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Vishal Vashistha, M.D.

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Apar Kishor Ganti, MD

has a financial relationship (Independent contractor) with Beigene Ltd;.
has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with Mirati Therapeutics;.
has a financial relationship (Other) with YmAbs Therapeutics;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Regeneron Pharmaceuticals;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Independent contractor) with Flagship Biosciences;.

Seema Harichand-Herdt

has no relevant financial relationships to disclose at this time.

Mark Klein, M.D.

has a financial relationship (Grant Or Contract) with Galera;.
has a financial relationship (Grant Or Contract) with Cellworks;.
Speaker/Topic Presenter(s)

Vijaya Bhatt, MBBS, MS

has a financial relationship (Professional Services) with BMJ Best Practice;.
has a financial relationship (Professional Services) with Current Problems in Cancer;.
has a financial relationship (Professional Services) with Protagonist;.
has a financial relationship (Professional Services) with Imugene;.

Chandrikha Chandrasekharan, MBBS

has no relevant financial relationships to disclose at this time.

Muhammad Furqan

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Grant Or Contract) with Aprea;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Inbrx;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Poseida;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with BeiGene;.
has a financial relationship (Grant Or Contract) with Genmab;.
has a financial relationship (Grant Or Contract) with Immunocore;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Jazz Pharma;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Elicio;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Jacobio;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Sophia;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Omega Therapeutics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Checkmate;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Mirati;.
has a financial relationship (Grant Or Contract) with Tempus;.

Tara Graff, DO MS

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with KITE;.
has a financial relationship (Independent contractor) with Genetench;.
has a financial relationship (Independent contractor) with Adaptive;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with AZ;.
has a financial relationship (Independent contractor) with Cellectar;.
has a financial relationship (Independent contractor) with Beigene;.

Robert Kratzke, Professor of Medicine

has a financial relationship (Professional Services) with Mirati;.

Mridula Krishnan

has no relevant financial relationships to disclose at this time.

Eric Mou

has no relevant financial relationships to disclose at this time.

Sneha Phadke, DO, MPH

has a financial relationship (Professional Services) with Starling Pharmaceuticals;.

Christopher Strouse, MD

has a financial relationship (Independent contractor) with Pfizer;.

Benjamin Teply, MD, MS

has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Eli Lilly;.
has a financial relationship (Professional Services) with Seagen;.

Amulya Yellala, MBBS, MD

has no relevant financial relationships to disclose at this time.

Yousef Zakharia, MD

has a financial relationship (Professional Services) with Seagen ;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Eisai ;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead ;.

William Zeitler

has no relevant financial relationships to disclose at this time.

Nicholas Zorko, MD, PhD

has a financial relationship (Other) with Telix Pharmaceuticals;.
has a financial relationship (Other) with Caris Life Sciences ;.
Case Presenter(s)

Nicholas Zorko, MD, PhD

has a financial relationship (Other) with Telix Pharmaceuticals;.
has a financial relationship (Other) with Caris Life Sciences ;.
Moderator(s)

Jim Armitage, M.D.

has a financial relationship (Stock Options) with cardiff oncology;.
Planning committee(s)

Kartik Anand, MD

has a financial relationship (Other) with Biotheranostics, Inc;.
has a financial relationship (Stock Options) with Eli Lilly;.
has a financial relationship (Stock) with Crispr therapeutics;.

Madison Koppin, PharmD

has no relevant financial relationships to disclose at this time.

Amy Raedeker

has no relevant financial relationships to disclose at this time.

Bilal Rahim, MD, MSc

has no relevant financial relationships to disclose at this time.

Available Credit

  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.

Platinum Sponsor: 

We would like to thank the following exhibitors and sponsors for their support of this meeting.

NameTable NumberExhibit typeRep  Name
Abbvie2General ExhibitScott Vance
Agios3General ExhibitScott Milanowski
Alexion Astra Zeneca Rare Disease4General ExhibitKelly  Sigle
Amgen Onoclogy5General ExhibitNicole  Bailey
Astellas6General ExhibitVal Lang
Astrazeneca Table 11General ExhibitTom Wolfe
Astrazeneca Table 224Lunch PT & Premium Exhibit Cindy Curtis
Boehringer Ingelheim Oncology7General ExhibitRaul Jalmasco
Bristol Myers Squibb8General ExhibitMonica Taylor
Daiichi Sankyo9General ExhibitMax Rustan
Daiichi Sankyo - 2nd table11General ExhibitCraig Marker
Eisai12General ExhibitGregg Lucken
Eli Lilly and Company/Loxo@Lilly13General ExhibitPhilip M Rocca, Jr.
Exelixis14General ExhibitStacey Vance
GENENTECH, A MEMBER OF THE ROCHE GROUP15General ExhibitCHRIS HINK
Genmab16General ExhibitLindy Melcher
Gilead Sciences23Premium ExhibitJacqui Hansen
Glaxo Smith Kline40General ExhibitRenae VanZuiden
ImmunoGen18General ExhibitCarrie McGuire
Ipsen Biopharma19General ExhibitJulie  Bathke
Johnson & Johnson - - 3rd table20General ExhibitCarey Nahas
Johnson & Johnson - 2nd table34General ExhibitTara  Branecki 
Johnson and Johnson Solid Tumor42General ExhibitCatherine  Mixsell
Menarini Stemline21General ExhibitJohn Rysavy
Merck - table 122General ExhibitJennifer Coe
Merck - table 225General ExhibitRob Kloewer
Mirati Therapeutics- a Bristol-Myers Squibb Company26General ExhibitJennifer Gau
Natera27General ExhibitLawrence O'Brien
Novartis Oncology28General ExhibitKrista  Zepeda
Pfizer29General ExhibitMary  Bender
Pfizer Inc30General ExhibitTimothy  Devine
Pharmacyclics31General ExhibitAmy Marshall Freeman
Seagen32General ExhibitNicole Lester-Ekis
Secura Bio33General ExhibitBrenda Dickel
Servier35Break PT &  Premium ExhibitTeresa Nissen
SpringWorks Therapeutics36General ExhibitKevin Madoch
Taiho Oncology37General ExhibitCynthia Sudekum
Takeda Oncology38General ExhibitStacia McGrath
Tempus39General ExhibitMitch Gonzales

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.